Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease

NCT05256134 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05256134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05256134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Terminated
Start date
April 19, 2022
Completion date
March 13, 2023
Enrollment
25 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimers disease